PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Gregson, J.M.* ; Freitag, D.F.* ; Surendran, P.* ; Stitziel, N.O.* ; Chowdhury, R.* ; Burgess, S.* ; Kaptoge, S.* ; Gao, P.* ; Staley, J.R.* ; Willeit, P.* ; Nielsen, S.F.* ; Caslake, M.* ; Trompet, S.* ; Polfus, L.M.* ; Kuulasmaa, K.* ; Kontto, J.* ; Perola, M.* ; Blankenberg, S.* ; Veronesi, G.* ; Gianfagna, F.* ; Männistö, S.* ; Kimura, A.* ; Lin, H.* ; Reilly, D.F.* ; Gorski, M.* ; Mijatovic, V.* ; Munroe, P.B.* ; Ehret, G.B.* ; Thompson, A.* ; Uria-Nickelsen, M.* ; Malarstig, A.* ; Dehghan, A.* ; Vogt, T.F.* ; Sasaoka, T.* ; Takeuchi, F.* ; Kato, N.* ; Yamada, Y.* ; Kee, F.* ; Müller-Nurasyid, M. ; Ferrieres, J.* ; Arveiler, D.* ; Amouyel, P.* ; Salomaa, V.* ; Boerwinkle, E.* ; Thompson, S.G.* ; Ford, I.* ; Jukema, J.W.* ; Sattar, N.* ; Packard, C.J.* ; Al Shafi Majumder, A.* ; Alam, D.S.* ; Deloukas, P.* ; Schunkert, H.* ; Samani, N.J.* ; Kathiresan, S.* ; Nørdestgaard, B.G.* ; Saleheen, D.* ; Howson, J.M.M.* ; di Angelantonio, E.* ; Butterworth, A.S.* ; Danesh, J.*

Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles.

Eur. J. Prev. Cardiol. 24, 492-504 (2017)
DOI PMC
Open Access Green as soon as Postprint is submitted to ZB.
Aims Darapladib, a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), has not reduced risk of cardiovascular disease outcomes in recent randomized trials. We aimed to test whether Lp-PLA2 enzyme activity is causally relevant to coronary heart disease. Methods In 72,657 patients with coronary heart disease and 110,218 controls in 23 epidemiological studies, we genotyped five functional variants: four rare loss-of-function mutations (c.109+2T > C (rs142974898), Arg82His (rs144983904), Val279Phe (rs76863441), Gln287Ter (rs140020965)) and one common modest-impact variant (Val379Ala (rs1051931)) in PLA2G7, the gene encoding Lp-PLA2. We supplemented de-novo genotyping with information on a further 45,823 coronary heart disease patients and 88,680 controls in publicly available databases and other previous studies. We conducted a systematic review of randomized trials to compare effects of darapladib treatment on soluble Lp-PLA2 activity, conventional cardiovascular risk factors, and coronary heart disease risk with corresponding effects of Lp-PLA2-lowering alleles. Results Lp-PLA2 activity was decreased by 64% ( p = 2.4 × 10-25) with carriage of any of the four loss-of-function variants, by 45% ( p < 10-300) for every allele inherited at Val279Phe, and by 2.7% ( p = 1.9 × 10-12) for every allele inherited at Val379Ala. Darapladib 160 mg once-daily reduced Lp-PLA2 activity by 65% ( p < 10-300). Causal risk ratios for coronary heart disease per 65% lower Lp-PLA2 activity were: 0.95 (0.88-1.03) with Val279Phe; 0.92 (0.74-1.16) with carriage of any loss-of-function variant; 1.01 (0.68-1.51) with Val379Ala; and 0.95 (0.89-1.02) with darapladib treatment. Conclusions In a large-scale human genetic study, none of a series of Lp-PLA2-lowering alleles was related to coronary heart disease risk, suggesting that Lp-PLA2 is unlikely to be a causal risk factor.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
3.606
1.194
1
19
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Human genetics; coronary heart disease; darapladib; lipoprotein-associated phospholipase A2; target validation
Language english
Publication Year 2017
Prepublished in Year 2016
HGF-reported in Year 2016
ISSN (print) / ISBN 2047-4873
e-ISSN 2047-4881
Journal European Journal of Preventive Cardiology
Quellenangaben Volume: 24, Issue: 5, Pages: 492-504 Article Number: , Supplement: ,
Publisher Sage
Reviewing status Peer reviewed
Institute(s) Institute of Genetic Epidemiology (IGE)
POF-Topic(s) 30501 - Systemic Analysis of Genetic and Environmental Factors that Impact Health
Research field(s) Genetics and Epidemiology
PSP Element(s) G-504100-001
PubMed ID 27940953
DOI 10.1177/2047487316682186
Scopus ID 85014459877
Erfassungsdatum 2016-12-31
[➜Report correction]